Use of computer-assisted detection (CADe) colonoscopy in colorectal cancer screening and surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement

Summary and Recommendation

This statement conveys the European Society of Gastrointestinal Endoscopy (ESGE) position on the use of computer-aided detection (CADe) with artificial intelligence (AI) during colonoscopy for colorectal cancer (CRC) screening or surveillance. The ESGE position is informed by the BMJ Rapid Recommendation initiative and the approach of the MAGIC Evidence Ecosystem Foundation; these include systematic reviews of currently available evidence, supplemented by microsimulation modeling and patient values and preferences, for the benefits and harms of AI CADe devices during colonoscopy.

ESGE convened a panel of European experts for this Position Statement. On December 18, 2024, panel members voted on their preferred recommendation between two choices about CADe during colonoscopy for indications of CRC screening or polyp surveillance. Out of 19 eligible votes, 13 (68.4%) voted to recommend CADe for colonoscopy, and six panel members (31.6%) voted against. Therefore, the current ESGE statement is:

Recommendation

The panel believes that most well-informed patients who have already decided to undergo colonoscopy for screening or surveillance would favor CADe assistance during colonoscopy. This is due to the potential benefits, although limited, of reduction in colorectal cancer incidence and mortality.

This recommendation is weak, because the evidence is limited with considerable uncertainty of the evidence estimates, the absolute benefits for colorectal cancer incidence and mortality are small, and there is a patient burden associated with CADe (more polyp overdiagnosis and more colonoscopy surveillance).

Publication History

Article published online:
27 March 2025

• References

• 1 Qassem A. et al. Screening for colorectal cancer in asymptomatic average-risk adults: a guidance statement from the American College of Physicians (version 2). Ann Intern Med 2023; 176: 1092-1100
• 2 Ola I, Cardoso R, Hoffmeister M. et al. Utilization of colorectal cancer screening tests across European countries: a cross-sectional analysis of the European health interview survey 2018–2020. Lancet Reg Health Europe 2024; 41
• 3 Pilonis ND, Spychalski P, Kalager M. et al. Adenoma detection rates by physicians and subsequent colorectal cancer risk. JAMA 2024;
• 4 Bisschops R, Rutter MD, Areia M. et al. Overcoming the barriers to dissemination and implementation of quality measures for gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and United European Gastroenterology (UEG) Position Statement. Endoscopy 2021; 53: 196-202
• 5 Zorzi M, Antonelli G, Barbiellini Amidei C. et al. Adenoma detection rate and colorectal cancer risk in fecal immunochemical test screening programs: an observational cohort study. Ann Intern Med 2023; 176: 303-310
• 6 Soleymanjahi S, Huebner J, Elmansy L. et al. Artificial intelligence-assisted colonoscopy for polyp detection: a systematic review and meta-analysis. Ann Intern Med 2024; 177: 1652-1663
• 7 Messmann H, Bisschops R, Antonelli G. et al. Expected value of artificial intelligence in gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2022; 54: 1211-1231
• 8 Fouratan F, Vandvik PO, Helsingen LM. et al. BMJ Rapid Recommendations: Computer aided detection and diagnosis of polyps in adult patients undergoing colonoscopy: A living clinical practice guideline. BMJ 2025;
• 9 Halvorsen N, Hassan C, Correale L. et al. Benefits, burden, and harms of computer aided polyp detection with artificial intelligence in colorectal cancer screening: microsimulation modelling study. BMJ 2025; 3: e001446
• 10 van der Zander QEW, van der Ende-van Loon MCM, Janssen JMM. et al. Artificial intelligence in (gastrointestinal) healthcare: patients’ and physicians’ perspectives. Sci Rep 2022; 12: 16779
• 11 Bretthauer M, Loberg M, Wieszczy P. et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. N Engl J Med 2022; 387: 1547-1556
• 12 Bretthauer M, Kaminski MF, Loberg M. et al. Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial. JAMA Intern Med 2016; 176: 894-902
• 13 Lundberg FE, Birgisson H, Johannesen TB. et al. Survival trends in patients diagnosed with colon and rectal cancer in the nordic countries 1990–2016: The NORDCAN survival studies. Eur J Cancer 2022; 172: 76-84
• 14 Zorzi M, Antonelli G, Barbiellini Amidei C. et al. Adenoma detection rate and colorectal cancer risk in fecal immunochemical test screening programs: an observational cohort study. Ann Intern Med 2023; 176: 303-310
• 15 Wisse PHA, Erler NS, de Boer SY. et al. Adenoma detection rate and risk for interval postcolonoscopy colorectal cancer in fecal immunochemical test-based screening: A population-based cohort study. Ann Intern Med 2022; 175: 1366-1373
• 16 Pilonis N, Wieszczy P, Bugajski M. et al. Thresholds of adenoma detection rate and post-colonoscopy colorectal cancer risk. Gastroenterology 2022; 162: S-150
• 17 Kalager M, Wieszczy P, Lansdorp-Vogelaar I. et al. Overdiagnosis in colorectal cancer screening: Time to acknowledge a blind spot. Gastroenterology 2018; 155: 592-595
• 18 Hassan C, Ponchon T, Bisschops R. et al. European Society of Gastrointestinal Endoscopy (ESGE) Publications Policy – Update 2020. Endoscopy 2020; 52: 123-126